19:05 EDT Rhythm Pharmaceuticals (RYTM) trading resumes
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals trading halted, news pending
- Rhythm Pharmaceuticals: EMANATE Setback but Validated MC4R Mechanism and Pipeline Optionality Support Lowered $100 Buy Rating
- Rhythm price target lowered to $100 from $110 at H.C. Wainwright
- Rhythm Pharmaceuticals price target lowered to $130 from $140 at RBC Capital
- Maintaining a Buy: Setmelanotide’s PDUFA Catalyst and Subgroup Signals Offset EMANATE Miss